Fundraising Fox

Rekindle Therapeutics

Cambridge, US · Founded 2018 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

Board

DBDetlev Biniszkiewicz
Detlev BiniszkiewiczinBoard directorManaging Director at MPM BioImpact
EH
Ed HurwitzinBoard directorManaging Director at MPM Capital
BG
Bard GeesamanBoard directorManaging Partner at MPM Capital

Investors · 1

MPM BioImpactreportedBoston · $1M – $15Mvia Bard Geesaman · board

Reported raises · per SEC filings

Form D private placements

$1.1M disclosed across 1 round · 2018

▶$1.1MraisedNov 2018 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Detlev BiniszkiewiczExecutive Officer, Director
  • Ed HurwitzDirector
  • Bard GeesamanDirector
Offering amount
$6.5M
Amount sold
$1.1M
Minimum investment
$10K
First sale
Oct 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Rekindle Therapeutics's investors?
Rekindle Therapeutics's investors include MPM BioImpact.
How much funding has Rekindle Therapeutics raised?
Rekindle Therapeutics has disclosed $1.1M raised across 1 round.
Where is Rekindle Therapeutics headquartered?
Rekindle Therapeutics is headquartered in Cambridge, US.